Neuphoria Therapeutics Inc.

US$2.78As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:NEUPHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (61.70%)
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM (38.90%)
Mkt cap US$15.04M
ROIC (25.72%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$2.66
(4.35%)
272.52%
Buy 9|4|7|0|5
2Q26
3Q26
4Q26
1Q27
Earnings per share$
0.06
0.07
0.07
0.07
11.19%
12.59%
14.91%
14.85%
Revenue$M
1.165
1.202
1.171
1.182
6.41%
4.71%
(1.70%)
0.59%
Peers (US$15.04M)
Cap (US$)
PE
15.10M
0.082x
Capital
TTM
5Y
10Y
Leveragex
0.174
2.126
1.807
EBIT/Intx
2.123
0.333
0.341
Own earn%
(3.10)
30.49
38.37
Sh yield%
30.06
52.56
48.71
Owners
Insiders/Inst%
9.53
55.25
Short interest%
4.84
SBC / revenue%
0.28
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
18
Op margin range%
0–6
$1 testx
—
Incr. ROIC%
10